Breaking News

RSV Passive Immunization 69% Effective in Protecting Infants

February 10, 2024 • 6:15 am CST
Eurosurveillance paediatric hospital, Luxembourg, 2022–2023
(Precision Vaccinations News)

The journal Eurosurveillance Rapid Communication published a study on January 25, 2024, that concluded Beyfortus™ (Nirsevimab) was about 69% effective at preventing pediatric respiratory syncytial virus (RSV) hospitalizations in infants.

In the context of moderate to high immunization coverage (84%) among neonates, this study provides early real-world evidence of nirsevimab immunization protecting infants from severe RSV disease in Luxembourg.

In 2023, 241 children under five years of age were hospitalized with a laboratory-confirmed RSV infection, compared with 389 cases in 2022, representing decreases of 38% (389 vs. 241) in cases under five years of age and 69% (232 vs. 72) in cases of infants under six months old.

The researchers concluded, 'Our study shows the impact of nirsevimab in mitigating severe RSV disease among infants during the first RSV season following the national implementation of passive immunization achieving high coverage in Luxembourg. There was a significant increase in the age of hospitalized children, and most severe RSV-related hospitalizations occurred in non-immunized children."

In previous clinical trials. nirsevimab showed between 74% and 86% efficacy against medically-attended lower respiratory tract infections caused by RSV in healthy infants.

As of February 2024, Beyfortus's availability in the U.S. has significantly improved.

Our Trust Standards: Medical Advisory Committee

Share